Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-02986-9, published online 3 June 2024.
In the version of the article initially published, in the Japan row of Supplementary Fig. 2, the values for the columns “Evaluable patients” and “Patients with ORR” were originally both 8 but have now been amended to 9. A corrected Supplementary Information file has now been uploaded online.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Morschhauser, F., Dahiya, S., Palomba, M.L. et al. Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat Med 30, 2374 (2024). https://doi.org/10.1038/s41591-024-03175-4
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41591-024-03175-4
This article is cited by
-
Current and future therapies for follicular lymphoma
Experimental Hematology & Oncology (2024)
-
Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma
Blood Cancer Journal (2024)
